Morgan Stanley Chinook Therapeutics, Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$18.66 - $38.58 $2.93 Million - $6.05 Million	156,906 Added 62.3%	408,746 $15.7 Million
Q1 2023 May 15, 2023	SELL	$21.53 - $26.8 $649,581 - $808,582	-30,171 Reduced 10.7%	251,840 $5.83 Million
Q4 2022 Feb 14, 2023	SELL	$18.63 - $27.35 $64,217 - $94,275	-3,447 Reduced 1.21%	282,011 $7.39 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $958,217 - $1.28 Million	54,724 Added 23.72%	285,458 $5.61 Million
Q2 2022 Oct 27, 2022	BUY	$12.59 - $18.8 $1.21 Million - $1.8 Million	95,835 Added 71.04%	230,734 $4.04 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $1.21 Million - $1.8 Million	95,835 Added 71.04%	230,734 $4.04 Million
Q1 2022 Oct 27, 2022	SELL	$12.02 - $16.69 $1.15 Million - $1.6 Million	-95,835 Reduced 41.53%	134,899 $2.21 Million
Q1 2022 May 13, 2022	BUY	$12.02 - $16.69 $715,706 - $993,772	59,543 Added 79.02%	134,899 $2.21 Million
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $58,313 - $91,807	5,455 Added 7.8%	75,356 $1.23 Million
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $803,861 - $1.04 Million	69,901 New	69,901 $891,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.